Literature DB >> 16785114

Management of bladder, prostatic and pelvic floor disorders.

G Brisinda1, G Maria, A R Bentivoglio, F Cadeddu, G Marniga, F Brandara, A Albanese.   

Abstract

Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. Over the years, the number of primary clinical publications has grown exponentially, and still continues to increase. It has been shown that BoNT blocks cholinergic nerve endings in the autonomic nervous system but does not block non-adrenergic non-cholinergic responses mediated by nitric oxide (NO). The present paper reviews a number of recent clinical indications for urological and pelvic floor dysfunctions, such as overactive and neurogenic bladder, non-bacterial prostatitis, benign prostatic hyperplasia, chronic anal fissure, or conditions associated to hyperactivity of the puborectalis muscle during straining. These indications provide a new promising palette of indications for future usage of BoNT in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785114     DOI: 10.1007/bf03033935

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  88 in total

1.  Treatment of anal fissure.

Authors:  Richard L Nelson
Journal:  BMJ       Date:  2003-08-16

2.  Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Robert L Stephen; Vittorio Bini; Elisabetta Costantini; Massimo Porena
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

3.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

4.  Histopathology of the internal anal sphincter in chronic anal fissure.

Authors:  A C Brown; J M Sumfest; J V Rozwadowski
Journal:  Dis Colon Rectum       Date:  1989-08       Impact factor: 4.585

Review 5.  Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia.

Authors:  B Djavan; S Madersbacher; H C Klingler; K Ghawidel; A Basharkhah; S Hruby; C Seitz; M Marberger
Journal:  Tech Urol       Date:  1999-03

6.  Treatment of overactive bladder with botulinum toxin type B: a pilot study.

Authors:  Dennis Dykstra; Al Enriquez; Michael Valley
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-25

7.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

8.  Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.

Authors:  J D McConnell; M J Barry; R C Bruskewitz
Journal:  Clin Pract Guidel Quick Ref Guide Clin       Date:  1994-02

9.  Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia.

Authors:  Marcus Riccabona; Mark Koen; Monica Schindler; Beckers Goedele; Armin Pycha; Lukas Lusuardi; Stuart B Bauer
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

10.  Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.

Authors:  Alberto Albanese; Giuseppe Brisinda; Anna Rita Bentivoglio; Giorgio Maria
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

View more
  3 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Treatment of gastrointestinal sphincters spasms with botulinum toxin A.

Authors:  Giuseppe Brisinda; Nicola Sivestrini; Giuseppe Bianco; Giorgio Maria
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.